FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296475802> ?p ?o ?g. }

• W4296475802 abstract "<h3></h3> Cholangiocarcinoma (CCA) tumors have high genomic heterogeneity, with 40%–50% of patients with CCA harboring ≥1 clinically-actionable genetic alteration, including fibroblast growth factor receptor (FGFR)1–3 alterations. Pemigatinib is an oral, potent, selective FGFR1–3 inhibitor for the treatment of adults with previously treated, unresectable, locally advanced/metastatic CCA with an FGFR2 fusion or other rearrangement. Here we report the final results from an open-label, single-arm, multicenter phase 2 study evaluating the safety and efficacy of pemigatinib in patients with previously treated locally advanced or metastatic CCA (FIGHT-202; NCT02924376; EudraCT Number: 2016–002422-36). Eligible patients were ≥18 years old, with locally advanced/metastatic or surgically unresectable CCA that progressed after ≥1 prior therapy, documented FGF/FGFR status, Eastern Cooperative Oncology Group performance status ≤2, and adequate hepatic/renal function. Patients were separated into 3 cohorts based on confirmed FGF/FGFR status (cohort A, FGFR2 fusions or rearrangements; cohort B, other FGF/FGFR genetic alterations; cohort C, no FGF/FGFR genetic alterations). All patients received 13.5 mg pemigatinib once daily (2 weeks on/1 week off) until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR) in cohort A, as confirmed by independent central review. Secondary endpoints included ORR in cohorts B and C, duration of response, disease control rate, progression-free survival, overall survival, and safety across all cohorts. Overall, 147 patients were enrolled (cohort A, n=108; cohort B, n=20; cohort C, n=17; undetermined FGF/FGFR status, n=2). Median (range) age was 59.0 (26–78) years, 57.8% of patients were women, 70.7% were White, and 89.8% had intrahepatic CCA, including 99.1% in cohort A. Median (range) duration of follow-up was 45.4 (19.9–53.7) months. In total, 98.6% of patients discontinued treatment, most commonly for disease progression (n=105/147; 71.4%). In cohort A, ORR (95% CI) was 37.0% (27.9%–46.9%). Efficacy results are provided in the table 1. All patients reported treatment-emergent adverse events (TEAEs); the most common were hyperphosphataemia (58.5%), alopecia (49.7%), and diarrhoea (47.6%). Most TEAEs were grade 1/2 in severity; the most common grade ≥3 TEAE was hypophosphataemia (14.3%). Additionally, 91.8% of patients had a treatment-related AE, 4.1% had a fatal TEAE (all considered unrelated to pemigatinib treatment), and 10.2% discontinued pemigatinib due to a TEAE. In this analysis, pemigatinib continued to demonstrate durable response, prolonged survival, and a manageable safety profile in patients with advanced/metastatic CCA with FGFR2 fusions or rearrangements. These results further highlight the need for molecular testing in patients with CCA." @default.
• W4296475802 created "2022-09-21" @default.
• W4296475802 creator A5017504528 @default.
• W4296475802 creator A5018257387 @default.
• W4296475802 creator A5021680577 @default.
• W4296475802 creator A5031170152 @default.
• W4296475802 creator A5036400761 @default.
• W4296475802 creator A5049680516 @default.
• W4296475802 creator A5054141550 @default.
• W4296475802 creator A5054185860 @default.
• W4296475802 creator A5057795879 @default.
• W4296475802 creator A5059766169 @default.
• W4296475802 creator A5064688044 @default.
• W4296475802 creator A5072144086 @default.
• W4296475802 creator A5076767039 @default.
• W4296475802 creator A5079645039 @default.
• W4296475802 creator A5081273660 @default.
• W4296475802 creator A5084809433 @default.
• W4296475802 creator A5086593040 @default.
• W4296475802 creator A5090645179 @default.
• W4296475802 date "2022-09-01" @default.
• W4296475802 modified "2023-09-27" @default.
• W4296475802 title "P18 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202" @default.
• W4296475802 doi "https://doi.org/10.1136/gutjnl-2022-basl.69" @default.
• W4296475802 hasPublicationYear "2022" @default.
• W4296475802 type Work @default.
• W4296475802 citedByCount "1" @default.
• W4296475802 countsByYear W42964758022023 @default.
• W4296475802 crossrefType "proceedings-article" @default.
• W4296475802 hasAuthorship W4296475802A5017504528 @default.
• W4296475802 hasAuthorship W4296475802A5018257387 @default.
• W4296475802 hasAuthorship W4296475802A5021680577 @default.
• W4296475802 hasAuthorship W4296475802A5031170152 @default.
• W4296475802 hasAuthorship W4296475802A5036400761 @default.
• W4296475802 hasAuthorship W4296475802A5049680516 @default.
• W4296475802 hasAuthorship W4296475802A5054141550 @default.
• W4296475802 hasAuthorship W4296475802A5054185860 @default.
• W4296475802 hasAuthorship W4296475802A5057795879 @default.
• W4296475802 hasAuthorship W4296475802A5059766169 @default.
• W4296475802 hasAuthorship W4296475802A5064688044 @default.
• W4296475802 hasAuthorship W4296475802A5072144086 @default.
• W4296475802 hasAuthorship W4296475802A5076767039 @default.
• W4296475802 hasAuthorship W4296475802A5079645039 @default.
• W4296475802 hasAuthorship W4296475802A5081273660 @default.
• W4296475802 hasAuthorship W4296475802A5084809433 @default.
• W4296475802 hasAuthorship W4296475802A5086593040 @default.
• W4296475802 hasAuthorship W4296475802A5090645179 @default.
• W4296475802 hasConcept C126322002 @default.
• W4296475802 hasConcept C143998085 @default.
• W4296475802 hasConcept C170493617 @default.
• W4296475802 hasConcept C203092338 @default.
• W4296475802 hasConcept C535046627 @default.
• W4296475802 hasConcept C71924100 @default.
• W4296475802 hasConcept C72563966 @default.
• W4296475802 hasConcept C74373430 @default.
• W4296475802 hasConcept C82867764 @default.
• W4296475802 hasConceptScore W4296475802C126322002 @default.
• W4296475802 hasConceptScore W4296475802C143998085 @default.
• W4296475802 hasConceptScore W4296475802C170493617 @default.
• W4296475802 hasConceptScore W4296475802C203092338 @default.
• W4296475802 hasConceptScore W4296475802C535046627 @default.
• W4296475802 hasConceptScore W4296475802C71924100 @default.
• W4296475802 hasConceptScore W4296475802C72563966 @default.
• W4296475802 hasConceptScore W4296475802C74373430 @default.
• W4296475802 hasConceptScore W4296475802C82867764 @default.
• W4296475802 hasLocation W42964758021 @default.
• W4296475802 hasOpenAccess W4296475802 @default.
• W4296475802 hasPrimaryLocation W42964758021 @default.
• W4296475802 hasRelatedWork W1526776543 @default.
• W4296475802 hasRelatedWork W1981099772 @default.
• W4296475802 hasRelatedWork W2017952250 @default.
• W4296475802 hasRelatedWork W2075500765 @default.
• W4296475802 hasRelatedWork W21291533 @default.
• W4296475802 hasRelatedWork W2315085516 @default.
• W4296475802 hasRelatedWork W2358034211 @default.
• W4296475802 hasRelatedWork W2603773853 @default.
• W4296475802 hasRelatedWork W4283768971 @default.
• W4296475802 hasRelatedWork W4385199358 @default.
• W4296475802 isParatext "false" @default.
• W4296475802 isRetracted "false" @default.
• W4296475802 workType "article" @default.